The regulatory effect of UL-16 binding protein-3 expression on the cytotoxicity of NK cells in cancer patients

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Mou, Xiao ^a   Zhou, Yuepeng ^a   Jiang, Peng ^a   Zhou, Tong ^b   Jiang, Qian ^a   Xu, Chengcheng ^a   Liu, Hongli ^a   Zheng, Tingting ^a   Yuan, Guoyue ^a   Zhang, Yanyun ^c   Chen, Deyu ^a   Mao, Chaoming ^a  

^a AFFILIATED HOSPITAL OF JIANGSU UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; KLRK1 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; SIGNAL PEPTIDE; SMALL INTERFERING RNA; ULBP3 PROTEIN, HUMAN;

ANTAGONISTS AND INHIBITORS; BLOOD; COCULTURE; DOWN REGULATION; HUMAN; IMMUNOLOGY; K562 CELL LINE; METABOLISM; NATURAL KILLER CELL; NEOPLASM; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; COCULTURE TECHNIQUES; DOWN-REGULATION; GPI-LINKED PROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; K562 CELLS; KILLER CELLS, NATURAL; NEOPLASMS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84906542775     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep06138     Document Type: Article

References (35)

1. Topalian, S. L., Weiner, G. J. & Pardoll, D. M. Cancer immunotherapy comes of age. J Clin Oncol 29, 4828-4836 (2011).
2. Movsas, B. et al. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. J Clin Oncol 23, 2145-2154 (2005). (Pubitemid 46218706)
3. Ljunggren, H. G. & Malmberg, K. J. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 7, 329-339 (2007).
4. Moretta, L. & Moretta, A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J 23, 255-259 (2004). (Pubitemid 38294490)
5. Farag, S. S. & Caligiuri, M. A. Human natural killer cell development and biology. Blood Rev 20, 123-137 (2006). (Pubitemid 43786166)
6. Jamieson, A. M. et al. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 17, 19-29 (2002). (Pubitemid 34874615)
7. Raulet, D. H. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 3, 781-790 (2003). (Pubitemid 37328656)
8. Groh, V. et al. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci U S A 93, 12445-12450 (1996). (Pubitemid 26367163)
9. Pende, D. et al. Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol 31, 1076-1086 (2001).
10. Cosman, D. et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14, 123-133 (2001). (Pubitemid 32206515)
11. Ullrich, E., Koch, J., Cerwenka, A. & Steinle, A. New prospects on the NKG2D/ NKG2DL system for oncology. Oncoimmunology 2, e26097 (2013).
12. Diefenbach, A., Jensen, E. R., Jamieson, A. M. & Raulet, D. H. Rae1 and H60 ligands of theNKG2Dreceptor stimulate tumour immunity.Nature 413, 165-171 (2001). (Pubitemid 32867877)
13. Cerwenka, A., Baron, J. L. & Lanier, L. L. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of aMHC class I-bearing tumor in vivo. Proc Natl Acad Sci U S A 98, 11521-11526 (2001). (Pubitemid 32928761)
14. Carayannopoulos, L. N. et al. Ligands for murine NKG2D display heterogeneous binding behavior. Eur J Immunol 32, 597-605 (2002). (Pubitemid 34257536)
15. O'Callaghan, C. A., Cerwenka, A., Willcox, B. E., Lanier, L. L. & Bjorkman, P. J. Molecular competition for NKG2D: H60 and RAE1 compete unequally for NKG2D with dominance of H60. Immunity 15, 201-211 (2001). (Pubitemid 32816870)
16. Li, P. et al. Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA. Nat Immunol 2, 443-451 (2001). (Pubitemid 33706143)
17. Bauer, S. et al. Activation of NK cells and T cells by NKG2D, a receptor for stressinducible MICA. Science 285, 727-729 (1999).
18. Champsaur, M. & Lanier, L. L. Effect of NKG2D ligand expression on host immune responses. Immunol Rev 235, 267-285 (2010).
19. Rolle, A. et al. Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein. J Immunol 171, 902-908 (2003). (Pubitemid 36871403)
20. Pende, D. et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 62, 6178-6186 (2002). (Pubitemid 35244469)
21. de Kruijf, E. M. et al. NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study. BMC Cancer 12, 24 (2012).
22. Hilpert, J. et al. Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses. J Immunol 189, 1360-1371 (2012).
23. Groh, V., Wu, J., Yee, C. & Spies, T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419, 734-738 (2002). (Pubitemid 35177960)
24. Sconocchia, G. et al. The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions. Blood 106, 3666-3672 (2005). (Pubitemid 41609209)
25. Doubrovina, E. S. et al. Evasion from NK cell immunity by MHC class I chainrelated molecules expressing colon adenocarcinoma. J Immunol 171, 6891-6899 (2003). (Pubitemid 37532125)
26. Jinushi, M. et al. Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. J Hepatol 43, 1013-1020 (2005). (Pubitemid 41627987)
27. Holdenrieder, S. et al. Soluble MICA in malignant diseases. Int J Cancer 118, 684-687 (2006). (Pubitemid 43076018)
28. Wu, J. D. et al. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 114, 560-568 (2004). (Pubitemid 39572106)
29. McGilvray, R. W. et al. NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting. Clin Cancer Res 15, 6993-7002 (2009).
30. Lopez-Soto, A. et al. Regulation of NKG2D signaling during the epithelial-tomesenchymal transition. Oncoimmunology 2, e25820 (2013).
31. Lanier, L. L. A renaissance for the tumor immunosurveillance hypothesis. Nat Med 7, 1178-1180 (2001). (Pubitemid 33063762)
32. Groh, V. et al. Broad tumor-associated expression and recognition by tumorderived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci U S A 96, 6879-6884 (1999). (Pubitemid 29274978)
33. Song, H., Kim, J., Cosman, D. & Choi, I. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression. Cell Immunol 239, 22-30 (2006). (Pubitemid 43927656)
34. Waldhauer, I. & Steinle, A. Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res 66, 2520-2526 (2006).
35. Mao, C. et al. A monoclonal antibody against human UL16-binding protein 3. Hybridoma (Larchmt) 31, 203-208 (2012).